Top Markets
Coin of the day
Daiichi Sankyo Company, Limited Daiichi Sankyo Company, Limited

Daiichi Sankyo Company, Limited

DSNKY
Xếp hạng trong cổ phiếu #660
Daiichi Sankyo Company, Limited researches and develops, manufactures, imports,... Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabalin for pain treatment; teneligliptin/canagliflozin for type 2 diabetes mellitus treatment; lacosamide anti-epileptic agent; prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone disorders; teneligliptin for type 2 diabetes mellitus treatment; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine for treating Alzheimer's disease; and laninamivir for anti-influenza treatment. It also provides olmesartan, an antihypertensive agent; levofloxacin, an antibacterial agent; pravastatin for hypercholesterolemia treatment; and loxoprofen, an anti-inflammatory analgesic. In addition, the company offers colesevelam for treating hypercholesterolemia and type 2 diabetes mellitus treatment; and ferric carboxymaltose and iron sucrose injections for treating anemia. Further, it provides Lulu, a combination cold remedy; Loxonin S, an antipyretic analgesic /anti-inflammatory analgesic; Transino for melasma improvement and treating against spots and freckles; Minon, a skincare product; and Breath Labo and Clean Dental oral care products, as well as Silodosin for dysuria; Gefitinib for malignant tumours; Bicalutamide for prostate cancer; and Tamoxifen, an anti-breast cancer agent. Additionally, the company offers adsorbed cell culture-derived influenza, influenza HA, measles rubella combined, and mumps vaccines. It also provides pharmaceuticals and drugs for animals, cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates. It has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. The company was founded in 1899 and is headquartered in Tokyo, Japan.
Giá cổ phiếu
$17.64
Vốn hóa thị trường
$32.65B
Thay đổi (1 ngày)
-3.24%
Thay đổi (1 năm)
-23.70%
Quốc gia
JP
Giao dịch Daiichi Sankyo Company, Limited (DSNKY)

Danh mục

EPS của Daiichi Sankyo Company, Limited (DSNKY)
EPS tính đến December 2025 TTM: $1.05
Theo các báo cáo tài chính mới nhất và giá cổ phiếu của Daiichi Sankyo Company, Limited, EPS hiện tại của công ty (TTM) là $1.05. Vào cuối năm 2024, công ty có EPS là $0.69, tăng so với EPS năm 2023 là $0.43.
Lịch sử EPS của Daiichi Sankyo Company, Limited từ 2000 đến 2026
EPS vào cuối mỗi năm
Năm EPS Thay đổi
2026 (TTM) $1.05 1.13%
2025 $1.04 50.41%
2024 $0.69 61.24%
2023 $0.43 49.48%
2022 $0.29 -18.86%
2021 $0.35 -42.73%
2020 $0.62 42.60%
2019 $0.43 51.17%
2018 $0.29 20.23%
2017 $0.24 -32.61%
2016 $0.35 -72.19%
2015 $1.27 354.47%
2014 $0.28 -16.43%
2013 $0.33 464.59%
2012 $0.06 -85.19%
2011 $0.40 88.83%
2010 $0.21 -120.58%
2009 $-1.03 -327.81%
2008 $0.45 48.57%
2007 $0.30 -10.07%
2006 $0.34 -2.73%
2005 $0.35 10.33%
2004 $0.32 47.57%
2003 $0.21 -0.88%
2002 $0.22 -12.99%
2001 $0.25 -18.10%
2000 $0.30 0.00%
EPS cho các công ty hoặc đối thủ cạnh tranh tương tự
Công ty EPS Chênh lệch EPS Quốc gia
$23.00 2,086.94%
US
$6.60 527.56%
GB
$11.10 955.43%
US
$2.37 125.35%
US
$7.20 584.61%
CH